Home > Resources > Whitepapers > Digital Therapeutics: pharma’s threat or opportunity

Digital Therapeutics: pharma’s threat or opportunity

September 30, 2019

The DTx market is like the early days of the biologics revolution. “We are right at the beginning – it is a whole new therapeutic modality and we have the opportunity to create upwards of 100 products to increase efficacy across a range of disease conditions”. But does it represent and Threat or an Opportunity for Pharma?

Spotlight

Alliance Pharmaceuticals Limited

Alliance is a publicly owned international pharmaceutical company listed on AIM, part of the London Stock Exchange. We started trading in 1998 and have grown strongly to an annual turnover approaching £100 million. At the heart of our business sits a diverse team of dedicated, enthusiastic and experienced professionals who are committed to providing much needed medicines around the world.

OTHER WHITEPAPERS

10 Tips on Selecting Cartridge Dust Collection Equipment for Tablet Presses

whitePaper | December 28, 2022

Though tablet compression does not generate large volumes of fugitive dust, safe and efficient collection of whatever dust is created by this process is critical.

Deal-Making Roundup

whitePaper | November 19, 2022

In the second year of the pandemic, dealmaking continued to take place at record levels, maintaining much of the momentum created during 2020.

Application Notes & Whitepapers 2019

whitePaper | December 19, 2019

Welcome to European Pharmaceutical Review’s Application Notes & Whitepapers Supplement 2019. This year’s topics range from analytical techniques for bioprocess investigation, host cell protein analysis and Raman imaging to advice on outsourcing services for product characterisation.

How to Choose the Right Contract Manufacturing Organisation for Your Pharmaceutical Product

whitePaper | November 21, 2022

Contract manufacturing can enhance the drug development process by creating effective processes, increasing manufacturing efficiencies, and reducing overhead costs.

Infosys and Top Pharma Bring Digital Transformation to DrugManufacturing Data

whitePaper | April 1, 2022

In 2017, a top 20 global pharmaceutical company began a journey to digitally transform its pharmaceutical engineering and manufacturing capabilities by constructing a data integration and visualization platform, with strategic assistance and technical implementation provided by its partner Infosys.

Seize the digital momentum

whitePaper | January 23, 2023

Investments in biopharmaceutical (biopharma) research and development (R&D) continue to fuel innovation and shape the future of health. However, this year’s analysis demonstrates that despite impressive examples of innovative products the step-change in improved productivity seen in 2021 has not continued.

Digital Therapeutics: pharma’s threat or opportunity